Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 9, 2009 - Issue 6
Submit an article Journal homepage
195
Views
33
CrossRef citations to date
0
Altmetric
Drug Profile

Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma

Stéphane Oudard Department of Medical Oncology, Hôpital Georges Pompidou European Hospital, Medical Oncology Department, Paris Descartes University, 20 rue Leblanc, 75015 Paris, France. [email protected]
,
Jacques Medioni Hôpital Georges Pompidou European Hospital, Medical Oncology Department, Paris Descartes University, 20 rue Leblanc, 75015 Paris, France
,
Jorge Aylllon Hôpital Georges Pompidou European Hospital, Medical Oncology Department, Paris Descartes University, 20 rue Leblanc, 75015 Paris, France
,
Eduardo Barrascourt Hôpital Georges Pompidou European Hospital, Medical Oncology Department, Paris Descartes University, 20 rue Leblanc, 75015 Paris, France
,
Reza-Thierry Elaidi Hôpital Georges Pompidou European Hospital, Medical Oncology Department, Paris Descartes University, 20 rue Leblanc, 75015 Paris, France
,
José Balcaceres Hôpital Georges Pompidou European Hospital, Medical Oncology Department, Paris Descartes University, 20 rue Leblanc, 75015 Paris, France
&
Florian Scotte Hôpital Georges Pompidou European Hospital, Medical Oncology Department, Paris Descartes University, 20 rue Leblanc, 75015 Paris, France
 show all
Pages 705-717 | Published online: 10 Jan 2014

Citations (33)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Jung-Hyun Choi, Sung-Hoon Kim, Young-Hun Jeong, Sung Wook Kim, Kyung-Tai Min & Kyong-Tai Kim. (2019) hnRNP Q Regulates Internal Ribosome Entry Site-Mediated fmr1 Translation in Neurons. Molecular and Cellular Biology 39:4.
Read now
Robert Goldstein & Tim Meyer. (2011) Role of everolimus in pancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy 11:11, pages 1653-1665.
Read now
Stefan L Kojic, Scott S Strugnell & Sam M Wiseman. (2011) Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Review of Anticancer Therapy 11:3, pages 387-402.
Read now

Articles from other publishers (30)

Huiping Jiang, Jianqun Xiong, Lihua Tan, Ping Jin, Yi Sun, Lianjuan Yang & Jingwen Tan. (2022) In Vitro Interactions of Antifungal Agents and Everolimus Against Aspergillus Species. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Pankaj Ahluwalia, Ashis K Mondal, Nikhil S Sahajpal, Mumtaz V Rojiani & Ravindra Kolhe. (2021) Gene signatures with therapeutic value: emerging perspective for personalized immunotherapy in renal cancer. Immunotherapy 13:18, pages 1535-1547.
Crossref
Aswathy R. Devan, Ayana R. Kumar, Bhagyalakshmi Nair, Nikhil Ponnoor Anto, Amitha Muraleedharan, Bijo Mathew, Hoon Kim & Lekshmi R. Nath. (2021) Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma. Pharmaceuticals 14:7, pages 656.
Crossref
Brad Poore, Ming Yuan, Antje Arnold, Antoinette Price, Jesse Alt, Jeffrey A Rubens, Barbara S Slusher, Charles G Eberhart & Eric H Raabe. (2019) Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. Neuro-Oncology 21:2, pages 252-263.
Crossref
Kamila Maliszewska-Olejniczak, Klaudia K. Brodaczewska, Zofia F. Bielecka & Anna M. Czarnecka. 2018. Epithelial Cell Culture. Epithelial Cell Culture 47 66 .
Himalee S. Sabnis, Ranganatha R. Somasagara & Kevin D. Bunting. (2017) Targeting MYC Dependence by Metabolic Inhibitors in Cancer. Genes 8:4, pages 114.
Crossref
Ki Hyang Kim, Joo Hoon Kim, Ji Young Lee, Hyo Song Kim, Su Jin Heo, Ji Hyung Kim, Ho Young Kim & Sun Young Rha. (2016) Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08. Cancer Research and Treatment 48:4, pages 1286-1292.
Crossref
Michele Milella. (2016) Optimizing clinical benefit with targeted treatment in mRCC: “Tumor growth rate” as an alternative clinical endpoint. Critical Reviews in Oncology/Hematology 102, pages 73-81.
Crossref
Bryan Wei Chen, Wei Chen, Hui Liang, Hao Liu, Chao Liang, Xiao Zhi, Li-qiang Hu, Xia-Zhen Yu, Tao Wei, Tao Ma, Fei Xue, Lei Zheng, Bin Zhao, Xin-Hua Feng, Xue-li Bai & Ting-bo Liang. (2015) Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Molecular Cancer Therapeutics 14:8, pages 1805-1815.
Crossref
A. A. Krasheninnikov, Yu. Yu. Sundui, A. A. Kostin & A. D. Kaprin. (2015) Long-term use of targeted afinitor therapy for metastatic renal cell carcinoma. Onkologiya. Zhurnal imeni P.A.Gertsena 4:1, pages 78.
Crossref
Narges Baluch, Sushil Kumar, Reza Mokhtari & Sylvain Baruchel. 2014. Metronomic Chemotherapy. Metronomic Chemotherapy 157 172 .
Ourania Nicolatou-Galitis, Adamantia Nikolaidi, Ilias Athanassiadis, Erofili Papadopoulou & Stephen Sonis. (2013) Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 116:2, pages e110-e116.
Crossref
Jamal Joudeh, Joshua E. Allen, Avisnata Das, Varun Prabhu, Michael Farbaniec, Jeffrey Adler & Wafik S. El-Deiry. 2013. Impact of Genetic Targets on Cancer Therapy. Impact of Genetic Targets on Cancer Therapy 1 34 .
Marc Bosiers, Dierk Scheinert, Charles A Simonton & Lewis B Schwartz. (2012) Coronary and endovascular applications of the Absorb™ bioresorbable vascular scaffold. Interventional Cardiology 4:6, pages 621-631.
Crossref
Hugh Q. Zhao, Alexander Nikanorov, Renu Virmani & Lewis B. Schwartz. (2012) Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent-mediated delivery of everolimus. Journal of Vascular Surgery 56:6, pages 1680-1688.
Crossref
Chenfei Zhou, Jun Zhang, Ying Zheng & Zhenggang Zhu. (2012) Pancreatic neuroendocrine tumors: A comprehensive review. International Journal of Cancer 131:5, pages 1013-1022.
Crossref
Stéphane Oudard, Rokhaya Thiam, Laure S. Fournier, Jacques Medioni, Michele Lamuraglia, Florian Scotte, Elizabeth Fabre, Dennis Kim, Euloge Kpamegan, Ashok Panneerselvam & Charles A. Cuenod. (2012) Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 study. European Journal of Cancer 48:10, pages 1512-1518.
Crossref
Johannes Lammer, Dierk Scheinert, Frank Vermassen, Renate Koppensteiner, Klaus A. Hausegger, Herman Schroë, Rajeev M. Menon & Lewis B. Schwartz. (2012) Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. Journal of Vascular Surgery 55:2, pages 400-405.
Crossref
Philippe Caron, Gwenaëlle Gravis, Stéphane Oudard & Géraldine Pignot. (2011) Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : effets secondaires endocriniens et troubles métaboliques. Bulletin du Cancer 98:3, pages S47-S59.
Crossref
Jessica K. Altman, Antonella Sassano, Surinder Kaur, Heather Glaser, Barbara Kroczynska, Amanda J. Redig, Suzanne Russo, Sharon Barr & Leonidas C. Platanias. (2011) Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors. Clinical Cancer Research 17:13, pages 4378-4388.
Crossref
Camillo Porta, Susanne Osanto, Alain Ravaud, Miguel-Angel Climent, Ulka Vaishampayan, Dorothy A. White, Patricia Creel, Brenda Dickow, Patricia Fischer, Suzanne Sweeney Gornell, Federica Meloni & Robert J. Motzer. (2011) Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. European Journal of Cancer 47:9, pages 1287-1298.
Crossref
Nobutaka Furuya, Takao Kamai, Hiromichi Shirataki, Yoshiaki Yanai, Takehiko Fukuda, Tomoya Mizuno, Fumihiko Nakamura, Tsunehito Kambara, Kimihiro Nakanishi, Hideyuki Abe & Ken-Ichiro Yoshida. (2011) Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma. Cancer Immunology, Immunotherapy 60:6, pages 793-808.
Crossref
Eric Tartour, H. Pere, B. Maillere, M. Terme, N. Merillon, J. Taieb, F. Sandoval, F. Quintin-Colonna, K. Lacerda, A. Karadimou, C. Badoual, A. Tedgui, W. H. Fridman & S. Oudard. (2011) Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer and Metastasis Reviews 30:1, pages 83-95.
Crossref
Nicole A. Johnson, Bing-Hung Chen, Shian-Ying Sung, Chia-Hui Liao, Wan-Chi Hsiao, Leland W. K. Chung & Chia-Ling Hsieh. (2010) A novel targeting modality for renal cell carcinoma: human osteocalcin promoter-mediated gene therapy synergistically induced by vitamin C and vitamin D3. The Journal of Gene Medicine 12:11, pages 892-903.
Crossref
Steven Gabardi & Steven A. Baroletti. (2012) Everolimus: A Proliferation Signal Inhibitor with Clinical Applications in Organ Transplantation, Oncology, and Cardiology. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30:10, pages 1044-1056.
Crossref
. (2010) Current World Literature. Current Opinion in Urology 20:5, pages 443-451.
Crossref
Georgios Giamas, Yik L. Man, Heidrun Hirner, Joachim Bischof, Klaus Kramer, Kalimullah Khan, Sharmeen S. Lavina Ahmed, Justin Stebbing & Uwe Knippschild. (2010) Kinases as targets in the treatment of solid tumors. Cellular Signalling 22:7, pages 984-1002.
Crossref
Chie Nishioka, Takayuki Ikezoe, Jing Yang & Akihito Yokoyama. (2010) Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1. Apoptosis 15:7, pages 795-804.
Crossref
W Kimryn Rathmell & Paul A Godley. (2010) Recent updates in renal cell carcinoma. Current Opinion in Oncology 22:3, pages 250-256.
Crossref
Dudley W. Lamming & David M. Sabatini. 2010. 21 38 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.